Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

LASS1 antibody (AA 301-350)

This Mouse Polyclonal antibody specifically detects LASS1 in ELISA and WB. It exhibits reactivity toward Human and has been mentioned in 5+ publications.
Catalog No. ABIN564667

Quick Overview for LASS1 antibody (AA 301-350) (ABIN564667)

Target

See all LASS1 (CERS1) Antibodies
LASS1 (CERS1) (Ceramide Synthase 1 (CERS1))

Reactivity

  • 21
  • 5
  • 4
  • 2
  • 1
Human

Host

  • 19
  • 1
  • 1
Mouse

Clonality

  • 20
  • 1
Polyclonal

Conjugate

  • 11
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
This LASS1 antibody is un-conjugated

Application

  • 10
  • 10
  • 4
ELISA, Western Blotting (WB)
  • Binding Specificity

    • 7
    • 2
    • 2
    • 1
    • 1
    AA 301-350

    Purpose

    Mouse polyclonal antibody raised against a partial recombinant LASS1.

    Sequence

    YIVAFAAKVL TGQVHELKDL REYDTAEAQS LKPSKAEKPL RNGLVKDKRF

    Cross-Reactivity

    Human

    Characteristics

    Antibody Reactive Against Recombinant Protein.

    Immunogen

    LASS1 (NP_067090, 301 a.a. ~ 350 a.a) partial recombinant protein with GST tag.
  • Application Notes

    Optimal working dilution should be determined by the investigator.

    Restrictions

    For Research Use only
  • Format

    Liquid

    Buffer

    50 % glycerol

    Handling Advice

    Aliquot to avoid repeated freezing and thawing.

    Storage

    -20 °C

    Storage Comment

    Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.
  • Separovic, Breen, Joseph, Bielawski, Pierce, VAN Buren, Gudz: "Ceramide synthase 6 knockdown suppresses apoptosis after photodynamic therapy in human head and neck squamous carcinoma cells." in: Anticancer research, Vol. 32, Issue 3, pp. 753-60, (2012) (PubMed).

    Separovic, Breen, Joseph, Bielawski, Pierce, VAN Buren, Gudz: "siRNA-mediated down-regulation of ceramide synthase 1 leads to apoptotic resistance in human head and neck squamous carcinoma cells after photodynamic therapy." in: Anticancer research, Vol. 32, Issue 7, pp. 2479-85, (2012) (PubMed).

    Haddad, Khoury, Daoud, Kantar, Harati, Mousallem, Alzate, Meyer, Boustany: "CLN5 and CLN8 protein association with ceramide synthase: biochemical and proteomic approaches." in: Electrophoresis, Vol. 33, Issue 24, pp. 3798-809, (2012) (PubMed).

    Senkal, Ponnusamy, Bielawski, Hannun, Ogretmen: "Antiapoptotic roles of ceramide-synthase-6-generated C16-ceramide via selective regulation of the ATF6/CHOP arm of ER-stress-response pathways." in: FASEB journal : official publication of the Federation of American Societies for Experimental Biology, Vol. 24, Issue 1, pp. 296-308, (2010) (PubMed).

    Senkal, Ponnusamy, Rossi, Bialewski, Sinha, Jiang, Jazwinski, Hannun, Ogretmen: "Role of human longevity assurance gene 1 and C18-ceramide in chemotherapy-induced cell death in human head and neck squamous cell carcinomas." in: Molecular cancer therapeutics, Vol. 6, Issue 2, pp. 712-22, (2007) (PubMed).

  • Target

    LASS1 (CERS1) (Ceramide Synthase 1 (CERS1))

    Alternative Name

    LASS1

    Background

    Full Gene Name: LAG1 homolog, ceramide synthase 1
    Synonyms: CerS1,LAG1,MGC90349,UOG1

    Gene ID

    10715

    NCBI Accession

    NM_021267
You are here:
Chat with us!